In recent years, several preclinical and clinical trials have explored the combination of CSF1/CSF1R inhibitors with various immunotherapies, such as immune checkpoint blockade, chemotherapy, and radiotherapy in several tumor models [19–29]. The gene discussed is CSF1R; the disease is neoplasm.